Megadeal Ahead? Horizon In Takeover Talks With Big Pharma For $20bn+ Deal
Amgen, J&J And Sanofi All Keen
The Irish firm revealed it was in early conversations with Amgen, J&J and Sanofi regarding a possible takeover, with some experts touting the potential for a deal far surpassing the $20bn mark.
You may also be interested in...
Horizon Megadeal: J&J Out, Experts Say Sanofi Could Have Edge On Amgen
Janssen has dropped out of the running to acquire Irish biotech Horizon, leaving Sanofi and Amgen to vie over the potential megadeal, with some observers identifying the former as the better fit.
Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal
Amgen’s latest deal shows the biotech major’s need to replenish its portfolios and also the cool heads required when negotiations get heated.
NextPoint Could Treat PD-L1 Negative Cancer Patients With HHLA2-Targeted Approach
Emerging Company Profile: Backed by strong academic talent and a recent $80m fundraising, the US biotech is on a mission to address the unmet medical need in PD-L1 negative cancer by targeting the HHLA2 pathway.